Posted by Michael Wonder on 22 Nov 2019
Biogen’s top scientist nearly dares FDA not to approve Alzheimer’s drug
22 November 2019 - Biogen’s top scientist offered unflinching support Thursday for the efficacy of the company’s controversial Alzheimer’s drug called aducanumab, shrugging off outside skepticism and almost daring regulators not to approve it.
“I believe the drug works,” said Dr. Al Sandrock, Biogen’s head of research and development and chief medical officer, speaking at the STAT Summit. “I’m very excited about the prospect of getting the drug approved.”
In a statement emailed to STAT after this story ran, Biogen said, “Our focus is to follow the science. Biogen respects and appreciates the FDA review process.”
